Skip to content
10-K

Annual Report

Inmune Bio, Inc. INMB

0001213900-26-036370

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 30, 2026 26.59M sh
Shares Diluted FY 2025 · Dec 31, 2025 24.76M sh
Shares Diluted FY 2025 · Dec 31, 2024 19.94M sh
Capex FY 2025 · Dec 31, 2025 $1.04M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$22.58M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$33.36M
Cash And Equivalents FY 2025 · Dec 31, 2025 $24.75M
Cash And Equivalents FY 2025 · Dec 31, 2024 $20.92M
Stockholders Equity FY 2025 · Dec 31, 2025 $23.52M
Stockholders Equity FY 2025 · Dec 31, 2024 $32.1M
Stockholders Equity FY 2025 · Dec 31, 2023 $37.34M
Current Liabilities FY 2025 · Dec 31, 2025 $8.42M
Current Liabilities FY 2025 · Dec 31, 2024 $7.22M
Total Liabilities FY 2025 · Dec 31, 2025 $8.83M
Total Liabilities FY 2025 · Dec 31, 2024 $7.47M
Current Assets FY 2025 · Dec 31, 2025 $29.89M
Current Assets FY 2025 · Dec 31, 2024 $22.66M
Total Assets FY 2025 · Dec 31, 2025 $32.35M
Total Assets FY 2025 · Dec 31, 2024 $39.56M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.86
Eps Diluted FY 2025 · Dec 31, 2024 −$2.11
Eps Basic FY 2025 · Dec 31, 2025 −$1.86
Eps Basic FY 2025 · Dec 31, 2024 −$2.11
Sga Expense FY 2025 · Dec 31, 2025 $10.26M
Sga Expense FY 2025 · Dec 31, 2024 $9.48M
Rd Expense FY 2025 · Dec 31, 2025 $20.66M
Rd Expense FY 2025 · Dec 31, 2024 $33.17M
Net Income FY 2025 · Dec 31, 2025 −$45.93M
Net Income FY 2025 · Dec 31, 2024 −$42.08M
Operating Income FY 2025 · Dec 31, 2025 −$47.38M
Operating Income FY 2025 · Dec 31, 2024 −$42.64M
Revenue FY 2025 · Dec 31, 2025 $50K
Revenue FY 2025 · Dec 31, 2024 $14K